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Abstract This analysis evaluated the efficacy and safety
of bevacizumab as monotherapy and with irinotecan for
recurrent glioblastoma in community-based practices. Adult
patients with bevacizumab-naive, recurrent glioblastoma
initiating second-line treatment (July 2006–June 2010) were
identified using McKesson Specialty Health/US Oncology
Network health records. Overall (OS) and progression-free
survival (PFS) estimates were analyzed through July 2011
and compared for bevacizumab and non-bevacizumab
regimens using the log-rank test. An adjusted Cox propor-
tional hazards model assessed the effects of patient and
treatment characteristics on outcomes. The analysis identi-
fied 159 patients initiating second-line treatment with a
bevacizumab-monotherapy (n = 57), bevacizumab-combi-
nation (n = 79), or non-bevacizumab (n = 23) regimen.
Patient characteristics were generally similar across groups.
In the Cox analyses, OS (hazard ratio [HR] 0.51 [95 %
confidence interval (CI) 0.31–0.82]; univariate medians:
8.86 vs. 5.19 months) was significantly longer with beva-
cizumab-containing regimens. Median PFS was longer with
bevacizumab-containing regimens, but did not reach statis-
tical significance (HR 0.64 [95 % CI 0.38–1.09]; univariate
medians: 7.00 vs. 4.00 months). Analyses showed that each
bevacizumab treatment group relative to non-bevacizumab
had a reduced risk of death (bevacizumab-monotherapy
regimen: HR 0.56 [95 % CI 0.31–1.03] and bevacizumab-
combination regimen: HR 0.34 [95 % CI 0.21–0.68]). Pa-
tients receiving the bevacizumab-combination regimen
trended toward longer OS and PFS than those receiving the
bevacizumab-monotherapy regimen. Rates of bevacizumab-
related toxicities were consistent with clinical trial reports.
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Introduction
Glioblastoma, a high-grade malignant glioma, accounts for
the majority of all primary brain tumor diagnoses in adults
[1, 2]. Despite advances, prognosis remains poor, with a
14.6-month median overall survival (OS) in patients treated
with the current frontline standard of care of surgical re-
section followed by fractionated radiotherapy and temo-
zolomide [3, 4]. Recurrence is inevitable, and no
universally accepted standard treatment at progression has
been established in patients with unresectable disease [5].
Select patients with recurrent glioblastoma may be treated
with additional surgery, radiotherapy, and/or second-line
chemotherapy, including temozolomide, nitrosourea, cy-
clophosphamide, and platinum-based regimens [5]. Second-
line chemotherapy confers a modest benefit, and has been
associatedwith 6-month progression-free survival (PFS) rates
of up to 15 % and a median OS approaching 6 months in
patients with recurrent glioblastoma in phase 2 trials [6, 7].
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Glioblastoma is among the most highly vascularized tu-
mors, and is particularly suited to targeted antiangiogenic
therapy [8]. In 2009, bevacizumab, a humanizedmonoclonal
antibody against vascular endothelial factor (VEGF-A), was
approved as a single-agent for patients with recurrent
glioblastoma on the basis of phase 2 studies of bevacizumab
both alone and in combination with irinotecan which
demonstrated improvements in response rate and 6-month
PFS relative to historic controls [9, 10]. A number of addi-
tional phase 2 studies, as well as retrospective community-
practice-based studies have investigated bevacizumab in
combination with other agents for recurrent, bevacizumab-
naive glioblastoma, without signaling improved clinical ef-
ficacy over bevacizumab alone [11–23]. However, none of
these community-based observational studies provided
comparative outcomes data on bevacizumab-containing
versus non-bevacizumab-containing regimens. Similarly, no
randomized trials, to date, have been conducted in the re-
current setting to compare bevacizumab treatment to a
control group receiving treatment other than bevacizumab or
to alternate bevacizumab regimens, although one such study
is currently enrolling patients [24].
In the current study, we describe differences in treatment
characteristics and their association with efficacy and safety
outcomes for bevacizumab monotherapy, bevacizumab-
combination therapy, and non-bevacizumab–containing
therapy in a large community-practice cohort of patientswith
bevacizumab-naive glioblastoma at first recurrence.
Patients and methods
Data source
In this retrospective cohort study, demographic, clinical, and
treatment data were abstracted from theMcKesson Specialty
Health/US Oncology Network iKnowMed (iKM) electronic
health record (EHR) database. iKM is an oncology-specific
EHR system that captures outpatient practice encounter
history from 900 community-based oncology providers
across US Oncology Network practices or clinics in 39
states. For the timeframe of this study, iKM was active in
approximately 82 % of the network, capturing data on out-
patient medical oncology care for patients treated across 20
states. The study was conducted following approval by the
institutional review boards of McKesson Specialty Health
and US Oncology Network.
Baseline patient and clinical characteristics included age,
sex, body mass index (BMI), practice region, payer status,
blood pressure, and Karnofsky Performance Status (KPS).
Vital status information was supplemented with data from
the Social Security Death Index (SSDI). Additional data,
including treatment, concomitant medication use, line of
therapy, disease progression, adverse events, corticosteroid
use during second-line therapy, and time since first surgery
were captured through electronic chart reviews.
Patients
The study included patients with recurrent histologically
confirmed glioblastoma who initiated treatment following
first recurrence, or second-line treatment, during the 4-year
period between July 1, 2006, and June 30, 2010, with a
minimum of 1-year of follow-up time with data cutoff at
June 30, 2011. The analysis population met the following
inclusion criteria: (1) confirmed diagnosis of glioblastoma,
(2) receipt of care at any McKesson Specialty Health/US
Oncology Network site using the full iKM EHR system
before the start of second-line chemotherapy for glioblas-
toma, (3) age C18 years at diagnosis, and (4) at least two
patient visits to practices during the study period. Patients
were excluded if they were diagnosed with or treated for a
primary cancer other than glioblastoma during the study
period or were enrolled in a randomized clinical trial. Pa-
tients were divided into three groups on the basis of the
composition of second-line therapy after the failure of a
first-line regimen that did not include bevacizumab: be-
vacizumab monotherapy, bevacizumab therapy in combi-
nation with other treatments (bevacizumab combination),
or non-bevacizumab–containing therapy (non-bevacizum-
ab). There was no minimum duration of any component of
second-line therapy required.
Statistical analysis
Descriptive statistics with 95 % confidence intervals (CIs)
were used to summarize patient and disease characteristics;
characteristics were compared between groups using the
Chi squared or exact tests for categorical variables and the
F-test for continuous variables. OS was measured as the
time from the initiation of second-line therapy to death or
loss to follow-up. Patients alive at the end of follow-up
(June 30, 2011) were censored for OS analyses. PFS was
measured as the time from the initiation of second-line
therapy to disease progression or death. The date of disease
progression after the initiation of second-line therapy was
abstracted from patients’ charts and was based on the
physician’s notes of progressive disease and/or escalation
in line of therapy. Disease progression was determined by a
change in the line of therapy as documented in the iKM.
For all patients on second-line therapy, chart review was
performed and the line of therapy with initiation date (in-
dex date) was identified and maintained.
Estimates of PFS and OS with related 95 % CIs were
calculated using Kaplan–Meier methods. The log-rank test
was applied to compare survival time between treatment
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groups. A Cox proportional hazards model was developed
to assess independent effects of patient and treatment
characteristics on the survival outcomes of interest while
controlling for the following potential confounding vari-
ables: age (\ 60 years or C 60 years), sex, BMI (\25
or C25), KPS (100, 90, 80, or B70), blood pressure (pre-
hypertensive or hypertensive), payer status (Medicare,
private, or other), practice region (Midwest, Northwest,
South, or West), exposure to corticosteroids at the initiation
of second-line treatment (yes or no), degree of resection
(no biopsy, partial excision, or excision) and therapy (non-
bevacizumab, bevacizumab monotherapy or bevacizumab
combination) received in the second-line setting.
Propensity score-adjusted sensitivity analyses were con-
ducted to evaluate the relationship between treatment choice
and subsequent survival. These analyses are particularly
useful for studies with small sample sizes, and adjust for
preexisting group differences that may lead to differences in
treatment. Cox regression models, stratified on the quintiles
of the propensity score, were constructed. These evaluations
were conducted in all patients, and the scores determined for
each patient were used as an adjustment variable in the Cox
proportional hazard regression.
The median number of treatment cycles and duration of
treatment, with interquartile ranges (IQR), were calculated
for bevacizumab-containing regimens. Patients who re-
ceived only one dose of treatment or who remained on
treatment at the end of follow-up were excluded from these
analyses.
All statistical analyses were conducted using SAS 9.2
(SAS Institute, Inc., Cary, NC).
Results
Study population characteristics
In the iKM database, the care of 3041 patients with brain
cancer was documented between July 1, 2006, and June 30,
2011. Of these, a total of 209 patients were initially iden-
tified as having histologically confirmed glioblastoma and
no diagnosis of another major cancer; had initiated second-
line therapy for glioblastoma within the study period, and
were not participants in a randomized clinical trial within
the network. After chart review, patients were excluded
because of participation in a randomized clinical trial
outside of the network (n = 27), where they had received
bevacizumab as adjuvant or as first-line therapy (n = 20),
or had received second-line bevacizumab beyond the study
period (n = 3). Consequently, 159 patients were analyzed
in this study (bevacizumab monotherapy [n = 57]; beva-
cizumab combination [n = 79]; non-bevacizumab
[n = 23]) (Fig. 1).
There were 249 patients meeting the other inclusion
criteria that received first line therapy in the study period
but did not receive second-line therapy. Of these, 189 were
alive, 26 died prior to initiation of second-line therapy, and
one was lost to follow-up. Vital status data were missing
for 33 of the patients who only received first-line therapy in
the study period.
Patient demographics and treatment characteristics
Patient characteristics were similar in the treatment groups
with regard to sex, BMI, hypertension status, and KPS at
the start of second-line therapy (Table 1). Notably, patients
in the bevacizumab-combination group had a lower median
age at the start of second-line therapy (54 years) compared
with those receiving bevacizumab monotherapy (61 years)
or a non-bevacizumab regimen (58 years) (P = 0.0135). A
relatively high proportion of patients in the bevacizumab-
monotherapy group were treated in the South, whereas
patients in the non-bevacizumab group tended to be treated
in the West. Patients who received bevacizumab mono-
therapy or bevacizumab combination were more likely to
have private insurance (60 %) than patients who received
non-bevacizumab regimens (30 %).
The majority of patients in each group had received
surgery (inclusive of biopsy, complete resection or partial
resection) and radiation in an earlier treatment setting (see
Table 1). Overall median time since surgery, indicative of
time to first progression, was 11 months (range 2–124) for
all patients, with no significant differences observed be-
tween groups. The use of corticosteroids at the time of
starting second-line treatment was consistent across the
treatment groups.
The composition of second-line therapy varied between
the bevacizumab-combination and non-bevacizumab
groups (see Table 1). Patients who were treated with be-
vacizumab and another agent most commonly received
irinotecan with or without carboplatin (68/79). In contrast,
temozolomide was the preferential second-line che-
motherapy used for patients treated with non-bevacizumab
regimens (12/23), followed by lomustine-containing regi-
mens (4/23) and single-agent irinotecan (3/24). Treatment
sequence analysis revealed that an additional 3 patients in
the non-bevacizumab group were treated with temozolo-
mide as first line or adjuvant therapy.
In the bevacizumab-containing groups, the median
number of treatment cycles (6 [IQR: 4–12] vs. 8 [IQR:
4–14]) and the duration of treatment (98 days [IQR:
56–155] vs. 154 days [IQR: 71–269]) were shorter in the
bevacizumab-monotherapy group than in the bevacizumab-
combination group, respectively, although the interquartile
ranges were overlapping.
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Effectiveness outcomes
At the end of follow-up, 141 (89 %) patients had died, 17
(11 %) were lost to follow-up, and information was unavail-
able for 1 patient (0.6 %). In the overall population, the me-
dian OS from the beginning of second-line therapy was
8.41 months (95 % CI, 6.27–9.86) by unadjusted analyses;
the bevacizumab monotherapy, bevacizumab combination,
and non-bevacizumabgroups had unadjustedmedian survival
of 6.76, 10.24, and 5.19 months, respectively. The Kaplan–
Meier estimate forOSwas significantly longer inpatientswho
received second-line bevacizumab (monotherapy or combi-
nation) (8.86 months; 95 % CI 7.06–10.44) compared with
patients in the non-bevacizumab group (5.19 months; 95 %
CI 3.12–8.11) (log-rank test P = 0.0044) (Fig. 2a). When
evaluating all three treatment cohorts,OSwas increased in the
bevacizumab-combination group relative to both the beva-
cizumab-monotherapy and the non-bevacizumab groups
(log-rank test, P = 0.0091) (Fig. 2b).
The estimated median PFS in all patients treated with
bevacizumab (7.00 months; 95 % CI 6.00–9.00) was longer
than in those receiving a second-line regimen not containing
bevacizumab (4.00 months; 95 % CI 2.00–10.00), but this
did not reach statistical significance (log-rank test;
P = 0.0785) (Fig. 2c). The 6-month PFS rates in the com-
bined bevacizumab groups and the non-bevacizumab group
were 51.39 % (95 %CI 42.25–59.80) and 29.05 % (95 %CI
10.99–50.06), respectively. In the unadjusted analysis, the
median PFS in the bevacizumab-combination group was
9.00 months (95 % CI 6.00–12.00), and was significantly
longer than that reported in the other two cohorts (log-rank
test, P = 0.0116) (Fig. 2d).
After adjusting for confounding variables, the multivari-
able Cox model demonstrated that the use of second-line
bevacizumab was associated with significantly improved OS
(hazard ratio [HR] 0.45; 95 % CI 0.26–0.77), relative to the
use of non-bevacizumab regimens as second-line treatment,
while improvements in PFS (HR 0.69; 95 % CI 0.37–1.28),
were not statistically significant. Moreover, both beva-
cizumab monotherapy and bevacizumab-combination ther-
apy trended toward superior OS (HR 0.56 [95 % CI
0.31–1.03] and HR 0.34 [95 % CI 0.21–0.68], respectively;
P = 0.0039) and PFS (HR 0.98 [95 % CI 0.50–1.92] and
HR 0.52 [95 % CI 0.27–1.01 respectively; P = 0.0174)
when comparedwith non-bevacizumab therapy (Tables 3, 4).
In Cox models adjusted by propensity scores, similar
Fig. 1 Patient selection procedure. EHR electronic health record, IV intravenous
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Table 1 Patient and clinical characteristics at the time of second-line treatment by group












Median age, years (range)* 57 (19–82) 61 (30–77) 54 (24–82) 58 (19–78)
C60 years 69 (43) 31 (54) 27 (34) 11 (48)
Male sex 90 (57) 30 (53) 45 (57) 15 (65)
BMI, median (range) 27.0 (17.0–46.8) 26.6 (18.1–46.8) 27.6 (17.0–41.8) 28.1 (21.6–39.2)
C25.0 119 (75) 40 (70) 63 (80) 16 (70)
Practice region
Midwest 19 (12) 8 (14) 11 (14) 0 (0)
Northeast 30 (19) 8 (14) 18 (23) 4 (17)
South 53 (33) 27 (47) 18 (23) 8 (35)
West 57 (36) 14 (25) 32 (41) 11 (48)
Payer status*
Medicare 35 (22) 15 (26) 11 (14) 9 (39)
Private 88 (55) 33 (58) 48 (61) 7 (30)
Other 36 (23) 9 (16) 20 (26) 7 (30)
Blood pressure
Normala 58 (36) 22 (39) 27 (34) 9 (39)
Prehypertensionb 85 (53) 26 (46) 45 (57) 14 (61)
Hypertension (I and II)c 14 (9) 9 (16) 5 (6) 0 (0)
Missing 2 (1) 0 (0) 2 (3) 0 (0)
KPS
100 8 (5) 2 (4) 5 (6) 1 (4)
90 34 (21) 11 (19) 17 (22) 6 (26)
80 35 (22) 10 (17) 22 (28) 3 (13)
B70 48 (30) 20 (34) 19 (24) 9 (39)
Missing 34 (21) 14 (24) 16 (21) 4 (17)
Median Follow-up Time (months)* 8.41 6.76 10.24 5.19
Prior surgeryd 145 (91) 53 (91) 69 (88) 23 (100)
Median time since surgery, months (range)d 11 (2–124) 9 (3–51) 12 (3–124) 16 (2–52)
Cortiosteroidused,e 134 (84) 48 (83) 65 (83) 21 (91)
Prior radiation therapy 155 (97) 56 (98) 77 (97) 22 (96)
Second-line therapy (other than bevacizumab)
Irinotecan 63 (40) – 60 (76) 3 (13)
Carboplatin ? irinotecan 8 (5) – 8 (10) –
Carboplatin ? etoposide 1 (1) – – 1 (4)
Carboplatin 9 (6) – 7 (9) 2 (9)
Etoposide 1 (1) – – 1(1)
Temozolomide 14 (9) – 2 (3) 12 (52)
Carmustine 1 (1) – 1 (1) –
Lomustine-containing regimen 4 (3) – – 4 (17)
Sorafenib 1 (1) – 1 (1) –
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improvements in HRs for survival outcomes were observed
for both the bevacizumab monotherapy and bevacizumab-
combination therapy with respect to OS, and for the beva-
cizumab-combination therapy with respect to PFS when
compared to non-bevacizumab therapy (data not shown).
Multivariable analyses also showed that patients re-
ceiving bevacizumab combination had a trend toward
longer OS (HR 0.34; 95 % CI 0.21–0.68) and longer PFS
(HR 0.52; 95 % CI 0.27–1.01) than those receiving beva-
cizumab monotherapy. The Cox models, which included a
propensity score adjustment, indicated a HR for OS of 0.38
(95 % CI 0.25–0.58) and PFS of 0.61 (95 % CI 0.30–1.23)
in favor of bevacizumab-combination therapy. No addi-
tional factors (i.e., categories according to age, sex, BMI,
KPS, blood pressure status, payer status, practice region,
exposure to corticosteroids, or degree of resection) were
associated with improved survival outcomes (Tables 3, 4).
Only 29 patients (18 %) received third-line therapy; 13
patients in the second-line bevacizumab monotherapy
group, 9 patients in the second-line non-bevacizumab
group, and 7 patients in the bevacizumab combination
group received third-line therapy, respectively. A total of
107 patients (67 %) died prior to receiving third-line
therapy, 16 patients (10 %) were still receiving second-line
therapy at the end of the study period, and 7 patients (4 %)
had no additional data regarding the use of third-line
therapy.
Safety
In general, there was a low incidence of bevacizumab-as-
sociated adverse events in the bevacizumab-monotherapy
and bevacizumab-combination groups (Table 2). Venous
and arterial thrombosis (11 %) and treatment-related hy-
pertension (9 %) were adverse events reported most com-
monly among patients receiving bevacizumabmonotherapy.
In the bevacizumab-combination group, treatment-related
hypertension (9 %) and proteinuria (9 %) were observed
most frequently. Only three patients in the second-line non-
bevacizumab group reported treatment-related adverse
events (one case each of treatment-related hypertension,
gastrointestinal perforation, and thromboembolism).
At the start of second-line therapy, the percentage of
patients on corticosteroids was similar across the treatment
groups (78–83 %). Corticosteroid use decreased during
second-line treatment, with similar reductions in the
number of patients requiring corticosteroids across all
groups (Table S1).
Discussion
This novel analysis of EHR data in a large community-
practice setting allowed for the investigation of clinical
outcomes in patients treated with second-line bevacizumab
monotherapy, bevacizumab-combination regimens, and
non-bevacizumab–containing treatment for recurrent
glioblastoma. The analysis revealed that the use of beva-
cizumab-containing regimens, when compared separately
or together, was associated with significantly improved
survival relative to the use of regimens that did not include
bevacizumab. In the multivariable analysis that combined
all patients receiving bevacizumab, the HRs for OS and
PFS were 0.45 and 0.69, respectively. These data are
consistent with reports from phase 2 trial analyses in pro-
gressive glioblastoma, including the pivotal BRAIN study
Table 1 continued













Biopsy and partial 92 (58) 34 (60) 44 (56) 14 (61)
Complete excision 62 (39) 20 (35) 33 (42) 9 (39)
Missing 5 (3) 3 (5) 2 (2) 0 (0)
BM, body mass index, KPS Karnofsky performance status
* Statistically significant at P\ 0.05
a Systolic reading\120 mm Hg and diastolic reading\80 mm Hg
b Systolic reading of 120–139 mm Hg or diastolic reading of 80–89 mm Hg
c Hypertension I: Systolic reading of 140–159 mm Hg or diastolic reading of 90–99 mm Hg; hypertension II: systolic reading C160 mm Hg or
diastolic reading C100 mm Hg
d Data were obtained from both iKM database and electronic chart review; other variables were extracted from iKM
e Collected at any time point of the study period
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[9]. In addition, the median OS and PFS values (8.86 and
7.00 months, respectively) in the combined bevacizumab
group are similar to outcomes reported in a meta-analysis
of bevacizumab treatment for recurrent glioblastoma (me-
dian OS and time to progression of 9.3 and 6.1 months,
respectively) [25] as well as those reported in retrospective
studies (range of median OS values: 8.5–11.5 months;
range of median PFS values: 4.3–7.6 months) [18–20, 22].
This concordance provides some assurance that the data
from the current analysis reflect clinical practice.
Subgroup analyses also revealed a trend toward both
longer OS (HR 0.38; 95 % CI 0.25–0.58) and PFS
(HR 0.61; 95 % CI 0.30–1.23) for patients treated with
bevacizumab combination than those treated with beva-
cizumab monotherapy. To our knowledge, no previous
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Fig. 2 Kaplan-Meier estimates of OS and PFS for patients with
recurrent glioblastoma: a OS for patients receiving second-line
bevacizumab-containing therapy or non-bevacizumab therapy and
b OS for patients receiving second-line bevacizumab monotherapy,
bevacizumab-combination, or non-bevacizumab therapy. c PFS for
patients receiving second-line bevacizumab-containing therapy or
non-bevacizumab therapy and d second-line bevacizumab mono-
therapy, bevacizumab-combination, or non-bevacizumab therapy. CI
confidence interval, HR hazard ratio, OS overall survival, PFS
progression-free survival
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chemotherapy to bevacizumab in recurrent glioblastoma. In
the BRAIN study, Friedman and colleagues reported that
95 % CIs for median OS and PFS were largely overlapping
between the bevacizumab monotherapy and bevacizumab-
irinotecan arms, although the study was neither designed
nor powered to compare treatment arms [9].
Importantly, the multivariable analyses in the present
analysis controlled for a number of patient and disease
characteristics. While the median age in the bevacizumab-
combination group was younger than in the bevacizumab-
monotherapy group, age was not significantly associated
with either OS or PFS in this analysis. There did, however,
appear to be differences in the duration of treatment in the
two bevacizumab groups, which may have impacted
outcomes.
The current analysis found that clinical factors, includ-
ing age, sex, KPS, and degree of resection at the start of
second-line treatment, were not prognostic for survival.
While these findings are congruous with those from a meta-
analysis of phase 2 bevacizumab salvage trials for recurrent
glioblastoma [26], pooled analyses from a number of re-
search groups have shown significant associations between
Table 2 Adverse events of any grade related to second-line treatment by group






combination (n = 79)
Non-bevacizumab
(n = 23)
Treatment-related hypertension 13 (8) 5 (9) 7 (9) 1 (4)
Hemorrhage/bleeding 2 (1) 2 (4) – –
Cerebral hemorrhage 2 (1) 2 (4) – –
Other hemorrhage – – – –
Gastrointestinal perforation 4 (3) – 3 (4) 1 (4)
Thromboembolic eventsb 12 (8) 6 (11) 5 (6) 1 (4)
Proteinuria 9 (6) 2 (4) 7 (9) –
Wound-healing complicationsc 2 (1) 1 (2) 1 (1) –
Abscesses and fistulae 1 (1) – 1 (1) –
a Multiple adverse events were possible in a single patient
b Including venous and arterial thromboembolic events
c Including infections associated with postsurgical wounds
Table 3 Cox proportional hazards analysis of OS
Category Reference (n) Variable (n) HR (95 % CI)
Treatment cohort Non-bevacizumab (n = 23) Bevacizumab monotherapy (n = 58) 0.56 (0.31–1.03)
Bevacizumab combination (n = 78) 0.34 (0.21–0.68)
Age \60 years (n = 90) C60 years (n = 69) 0.71 (0.45–1.12)
Sex Female (n = 69) Male (n = 90) 0.99 (0.66–1.51)
BMI \25 (n = 40) C25 (n = 119) 1.09 (0.69–1.74)
Region Midwest (n = 19) Northwest (n = 30) 0.99 (0.49–1.99)
South (n = 53) 0.82 (0.42–1.58)
West (n = 57) 1.14 (0.59–2.19)
Baseline KPS 100 (n = 7) 90 (n = 33) 1.15 (0.43–3.04)
80 (n = 33) 1.10 (0.42–2.90)
B70 (n = 45) 0.75 (0.28–1.99)
Missing (n = 41) 1.15 (0.43–3.03)
Baseline BP Normal (n = 58) Pre-hypertension (n = 85) 0.91 (0.59–1.39)
Hypertension (n = 14) 0.94 (0.45–1.96)
Payor status Medcare (n = 35) Private (n = 88) 0.93 (0.53–1.65)
Other (n = 22) 1.35 (0.70–2.60)
Baseline steroid No (n = 14) Yes (n = 126) 0.75 (0.37–1.49)
Excision Biopsy and partial (n = 92) Complete excision (n = 62) 1.22 (0.83–1.81)
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age, performance status, and/or corticosteroid use on sur-
vival in recurrent glioma trials [27–29].
Bevacizumab treatment appeared to be well tolerated,
and the incidence of bevacizumab-related adverse events
was similar to that observed in previous studies in recurrent
glioblastoma [9–11]. The incidence of intracranial hemor-
rhage was low, with only two reported cases (4 %) in the
bevacizumab-monotherapy group.
A number of limitations are inherent in the study design.
EHR data are not collected for comparative research pur-
poses but for clinical practice reasons, and variations in
data-collection methods and the reporting practices of in-
dividual physicians may exist [30]. To circumvent potential
misclassification errors, electronic chart reviews were
conducted to validate EHR data for critical parameters and
information from the SSDI was used to supplement vital
status data.
Other limitations include the lack of integration of
proposed Response Assessment in Neuro-Oncology criteria
[31], heterogeneity of treatments in the bevacizumab-
combination and non-bevacizumab groups, the possibility
of unobserved selection bias that cannot be accounted for
by statistical adjustment, the retrospective observational
nature of the study, and the small size of the patient
population receiving non-bevacizumab treatment. The au-
thors recognize that a relatively small number of patients
received third-line therapy (approximately 18 % of all
patients in the study cohort). This is lower than is observed
in prospective clinical trials, and is explained by the ret-
rospective nature of the study in which the majority of
patients died before receiving third-line therapy and others
were still receiving second-line therapy at the end of the
study period. Additionally, the presence of radiation
necrosis was not documented among patients receiving
second line therapy in this study, therefore bias resulting
from this potential therapeutic benefit of bevacizumab
cannot be excluded from the analysis [32]. Treatment
patterns supported within the McKesson evidence-based
guidelines may also differ to some degree from treatment
patterns in other community-based practices, as well as
from sites not utilizing the full EHR capabilities. As this
was not a prospective study, it is possible that selection
bias may have influenced the results, since treating physi-
cians may have based treatment decisions on patient
characteristics such as overall fitness and/or comorbidities.
Lastly, prognostic biomarker data were not available for
our study patients, which may introduce important biolo-
gical imbalances into the study arms, as several prognostic
molecular markers have previously been identified and
efforts continue to identify markers with predictive value
[33–35].
Conclusions
In this retrospective study of patients with recurrent
glioblastoma, bevacizumab-containing regimens were as-
sociated with significant improvements in OS and PFS
relative to non-bevacizumab regimens by unadjusted and
multivariable analyses. Despite the limitations inherent in
Table 4 Cox proportional hazards analysis of PFS
Category Reference (n) Variable (n) HR (95 % CI)
Treatment cohort Non-bevacizumab (n = 23) Bevacizumab monotherapy (n = 58) 0.98 (0.50–1.92)
Bevacizumab combination (n = 78) 0.52 (0.27–1.01)
Age \60 years (n = 90) C60 years (n = 69) 1.03 (0.63–1.67)
Sex Female (n = 69) Male (n = 90) 1.21 (0.79–1.87)
BMI \25 (n = 40) C25 (n = 119) 0.94 (0.57–1.53)
Region Midwest (n = 19) Northwest (n = 30) 1.34 (0.65–2.77)
South (n = 53) 0.73 (0.37–1.43)
West (n = 57) 0.98 (0.49–1.96)
Baseline KPS 100 (n = 7) 90 (n = 33) 1.91 (0.52–6.99)
80 (n = 33) 1.17 (0.31–4.40)
B70 (n = 45) 1.38 (0.37–5.11)
Missing (n = 41) 1.39 (0.37–5.15)
Baseline BP Normal (n = 58) Pre-hypertension (n = 85) 0.77 (0.49–1.19)
Hypertension (n = 14) 1.01 (0.47–2.16)
Payor status Medcare (n = 35) Private (n = 88) 1.52 (0.83–2.78)
Other (n = 22) 1.57 (0.75–3.29)
Baseline steroid No (n = 14) Yes (n = 126) 0.65 (0.31–1.33)
Excision Biopsy and partial (n = 92) Complete excision (n = 62) 1.11 (0.72–1.71)
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the study design, the use of a large, geographically dis-
persed cohort of community-based patients, confirmatory
propensity score adjusted analyses, and consistency with
previously reported findings, further supports the clinical
value and acceptable safety profile of bevacizumab treat-
ment for progressive, bevacizumab-naive glioblastoma in a
real-world setting. Recently completed phase 3 trials in-
vestigated the incorporation of bevacizumab into frontline
regimens for newly diagnosed disease [36, 37] and did not
demonstrate an improvement in overall survival. However,
this retrospective study complements previous prospective
results supporting the clinical value of bevacizumab in the
treatment of recurrent glioblastoma.
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